直接抗病毒治疗减缓HCV感染合并CKD患者的肾功能下降
基线eGFR<60者年下降从-5.98改善至-1.32 ml/min/1.73m2,基线eGFR>60者无改善,非糖尿病人群白蛋白尿显著改善。
要点
- 基线eGFR<60的HCV患者接受DAA后肾功能下降速度显著减缓。
- 基线eGFR>60者治疗后eGFR年下降反而略增,需关注。
- 白蛋白尿改善仅见于非糖尿病患者。
核心结论
- HCV感染合并CKD患者接受DAA治疗可能减缓肾功能下降。
研究设计与样本
- 平均年龄56岁,64%男性,71%白人,21%糖尿病,42%肝硬化。
- 比较DAA治疗前3年与治疗后eGFR年下降斜率及治疗前后白蛋白尿。
主要发现
- 基线eGFR<60者治疗前3年eGFR年下降-5.98 ml/min/1.73m2(95%CI -7.30至-4.67),治疗后为-1.32 ml/min/1.73m2(95%CI -4.50至1.88)。
- 基线eGFR>60者治疗前3年eGFR年下降-1.43 ml/min/1.73m2(95%CI -1.78至-1.08),治疗后为-2.32 ml/min/1.73m2(95%CI -3.36至-1.03)。
- 非糖尿病患者白蛋白尿显著改善,糖尿病患者无显著改善。
- eGFR改善的预测因素包括基线存在CKD和非糖尿病。
- 急性肾损伤事件罕见,共29例,76%与抗病毒治疗无关。
临床怎么用
- 对HCV感染合并CKD(尤其eGFR<60)患者,可考虑DAA治疗以减缓肾功能下降。
- 糖尿病合并HCV感染患者即使接受DAA,白蛋白尿改善可能有限。
局限性
- 回顾性观察性设计,可能存在混杂偏倚。
- 未设未治疗对照组,因果推断受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hepatitis C virus (HCV) infection is common and can accelerate chronic kidney disease (CKD) progression. Direct-acting antiviral (DAA) therapies against hepatitis C have consistently shown rates of sustained viral remission. However, the effect on kidney function is unknown. In a retrospective observational cohort study of HCV-infected patients receiving DAA therapies from 2013 to 2017, the slopes of estimated glomerular filtration rate (eGFR) decline were compared in the three years before DAA therapy to the slope after therapy. Pre- and post-treatment albuminuria values were also compared. In all, 1,178 patients were included; mean age of 56, 64% male, 71% white, 21% were diabetic, and 42% with cirrhosis. In patients with eGFR less than 60ml/min per 1.73m2, the annual decline in eGFR in the three years prior to treatment was -5.98 ml/min per year (95% confidence interval -7.30 to -4.67) and improved to -1.32 ml/min per year (95% confidence interval -4.50 to 1.88) after DAA therapy. In patients with eGFR greater than 60ml/min per 1.73m2 the annual decline in eGFR in the three years prior to treatment was -1.43 ml/min per year (95% confidence interval -1.78 to -1.08) and after DAA therapy was -2.32 ml/min per year (95% confidence interval -3.36 to -1.03). Albuminuria improved significantly in patients without diabetes, but not in those with diabetes. Predictors of eGFR improvement included having CKD at baseline and being non-diabetic. Events of acute kidney injury were rare, occurring in 29 patients, and unrelated to antiviral therapy in 76% of cases. Thus, DAA therapy for HCVs infection may slow CKD progression.
引用
- Sise ME, Chute DF, Oppong Y, et al. Direct-acting antiviral therapy slows kidney function decline in patients with Hepatitis C virus infection and chronic kidney disease. Kidney Int. 2019. PMID: 31337501. doi:10.1016/j.kint.2019.04.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。